ATE302007T1 - Kombination von lumilysergol und riluzol für die vorbeugung und/oder behandlung von motoneuronalen erkrankungen - Google Patents

Kombination von lumilysergol und riluzol für die vorbeugung und/oder behandlung von motoneuronalen erkrankungen

Info

Publication number
ATE302007T1
ATE302007T1 AT00981467T AT00981467T ATE302007T1 AT E302007 T1 ATE302007 T1 AT E302007T1 AT 00981467 T AT00981467 T AT 00981467T AT 00981467 T AT00981467 T AT 00981467T AT E302007 T1 ATE302007 T1 AT E302007T1
Authority
AT
Austria
Prior art keywords
lumilysergol
riluzole
prevention
treatment
combination
Prior art date
Application number
AT00981467T
Other languages
English (en)
Inventor
Michel Dib
Jean-Marie Stutzmann
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE302007T1 publication Critical patent/ATE302007T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00981467T 1999-12-01 2000-11-28 Kombination von lumilysergol und riluzol für die vorbeugung und/oder behandlung von motoneuronalen erkrankungen ATE302007T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9915139A FR2801793B1 (fr) 1999-12-01 1999-12-01 Association d'une ergoline et de riluzole et son utilisation comme medicament
PCT/FR2000/003314 WO2001039776A1 (fr) 1999-12-01 2000-11-28 Association d'une ergoline et du riluzole pour la prevention et le traitement des maladies motoneuronales

Publications (1)

Publication Number Publication Date
ATE302007T1 true ATE302007T1 (de) 2005-09-15

Family

ID=9552768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981467T ATE302007T1 (de) 1999-12-01 2000-11-28 Kombination von lumilysergol und riluzol für die vorbeugung und/oder behandlung von motoneuronalen erkrankungen

Country Status (10)

Country Link
EP (2) EP1464332A1 (de)
JP (1) JP5170926B2 (de)
AT (1) ATE302007T1 (de)
AU (1) AU1870501A (de)
DE (1) DE60022084T2 (de)
DK (1) DK1237552T3 (de)
ES (1) ES2245651T3 (de)
FR (1) FR2801793B1 (de)
MX (1) MXPA02005482A (de)
WO (1) WO2001039776A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544835A (ja) 2005-05-10 2008-12-11 ジュート−ヒェミー アクチェンゲゼルシャフト マイコトキシン吸着のためのステべンサイトの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173489B (it) * 1984-03-27 1987-06-24 Inverni Della Beffa Spa Procedimento di preparazione di 1-metil-10alfa-metossilumilisergolo e di suci esteri,e intermedi per la loro preparazione
IT1252163B (it) * 1991-12-03 1995-06-05 Poli Ind Chimica Spa Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
US6060483A (en) * 1996-06-27 2000-05-09 Pharmacia & Upjohn S.P.A. Antineurodegenerative ergoline derivatives
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
CA2317811A1 (en) * 1998-01-09 1999-07-15 Mor-Research Applications Ltd. Treatment of dyskinesias
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite

Also Published As

Publication number Publication date
DK1237552T3 (da) 2005-12-19
AU1870501A (en) 2001-06-12
DE60022084D1 (de) 2005-09-22
ES2245651T3 (es) 2006-01-16
MXPA02005482A (es) 2002-11-29
EP1464332A1 (de) 2004-10-06
EP1237552A1 (de) 2002-09-11
DE60022084T2 (de) 2006-06-01
WO2001039776A1 (fr) 2001-06-07
EP1237552B1 (de) 2005-08-17
JP5170926B2 (ja) 2013-03-27
FR2801793B1 (fr) 2003-07-04
JP2003515561A (ja) 2003-05-07
FR2801793A1 (fr) 2001-06-08

Similar Documents

Publication Publication Date Title
DE69830512D1 (de) Heilmittel für neurodegenerative krankheiten
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
GB0318447D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
ES2098558T3 (es) Aplicacion del amino-2 trifluormetoxi-6 benzotiazol (riluzole) para obtener un medicamento destinado al tratamiento de las enfermedades de la motoneurona.
BR0112000A (pt) Amina, composto, álcool, epóxido, cetona, azida, composição, uso de uma amina, métodos de tratamento de um paciente, de inibição da atividade da beta-secretase, de clivagem da proteìna precursora de amilóide e da produção de peptìdeo amilóide e de placa beta-amilóide em um animal, de tratamento ou prevenção de uma doença distinguida por depósitos de beta-amilóide no cérebro e de produção de um complexo de beta-secretase, e, kit
DE60231407D1 (de) Hemmende antikörper der her3-aktivität
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
DK0690851T3 (da) Guanidin-derivater, som er anvendelige til behandling
ATE188119T1 (de) Heilmittel für wunden und hämorrhoiden
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
ATE128459T1 (de) Sulfonanilidderivat und arzneimittel.
ATE289805T1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
NO932947L (no) Antimikrobielt middel
SE0101082D0 (sv) Novel use
DE69303234D1 (de) Behandlung von entzündlichen Darmerkrankungen
ATE302007T1 (de) Kombination von lumilysergol und riluzol für die vorbeugung und/oder behandlung von motoneuronalen erkrankungen
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
GB9126874D0 (en) Medicaments
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1237552

Country of ref document: EP